Background: The appearance of Aβ42 peptide deposits is admitted to be a key event in the pathogenesis of Alzheimer's disease, although amyloid deposits also occur in aged non-demented subjects. Aβ42 is a degradation product of the amyloid protein precursor (APP). It can be catabolized by several enzymes, reabsorbed by capillaries or cleared into cerebrospinal fluid (CSF). The possible involvement of a decrease in CSF turnover in A4β2 deposit formation is up to now poorly known. We therefore investigated a possible relationship between a reduced CSF turnover and the CSF levels of the A4β2 peptide.To this aim, CSF of 31 patients with decreased CSF turnover were studied. These patients presented chronic hydrocephalus communicating or obstructive, which required surgery (ventriculostomy or ventriculo-peritoneal shunt). Nine subjects had idiopathic normal pressure hydrocephalus (iNPH), and the other 22 chronic hydrocephalus from other origins (oCH).The Aβ42 peptide concentration was measured by an ELISA test in 31 ventricular CSF samples and in 5 lumbar CSF samples from patients with communicating hydrocephalus.

Results: The 5 patients with lumbar CSF analysis had similar levels of lumbar and ventricular Aβ42. A significant reduction in Aβ42 ventricular levels was observed in 24 / 31 patients with hydrocephalus. The values were lower than 300 pg/ml in 5 out of 9 subjects with iNPH, and in 15 out of 22 subjects with oCH.

Conclusion: The decrease of CSF Aβ42 seems to occur independently of the surgical hydrocephalus aetiology. This suggests that a CSF reduced turnover may play an important role in the decrease of CSF Aβ42 concentration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117747PMC
http://dx.doi.org/10.1186/1471-2202-12-42DOI Listing

Publication Analysis

Top Keywords

csf turnover
16
csf
12
decrease csf
12
reduced csf
8
aβ42
8
ventricular aβ42
8
aβ42 peptide
8
chronic hydrocephalus
8
csf samples
8
lumbar csf
8

Similar Publications

Axatilimab, a high-affinity humanized immunoglobulin G4 monoclonal antibody against colony-stimulating factor 1 receptor (CSF-1R), is approved for the treatment of chronic graft-versus-host disease (cGVHD), and under investigation for idiopathic pulmonary fibrosis and solid tumors. The population pharmacokinetics (PK) and pharmacodynamics (PD) of axatilimab were characterized in healthy participants and patients with solid tumors or cGVHD using data from four clinical studies with 325 participants, including 278 patients with cGVHD. The model structure reflected the mechanism of action of axatilimab: blocking CSF-1R signaling with axatilimab reduces the circulating levels of cells in the mononuclear phagocytic cell lineage (including nonclassical monocytic cells (NCMCs) and Kupffer cells), resulting in increases in circulating enzymes owing to reduced clearance by Kupffer cells.

View Article and Find Full Text PDF

PrP lowering is effective against prion disease in animal models and is being tested clinically. Therapies in the current pipeline lower PrP production, leaving pre-existing PrP to be cleared according to its own half-life. We hypothesized that PrP's half-life may be a rate-limiting factor for the time to effect of PrP-lowering drugs, and one reason why late treatment of prion-infected mice is not as effective as early treatment.

View Article and Find Full Text PDF

Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer's disease.

Alzheimers Dement

November 2024

The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Article Synopsis
  • The study investigates how metabolic changes in the locus coeruleus (LC) relate to Alzheimer's disease (AD) and cognitive decline, raising questions about their progression and significance over time.
  • Using FDG-PET imaging, researchers analyzed LC metabolism in 604 ADNI participants and found that metabolic activity was higher in early preclinical stages, indicating potential cognitive resilience, but lower in later stages alongside cognitive impairment.
  • The results suggest that increased metabolism in the LC during early AD could help maintain memory function, while decreased levels in advanced stages may reflect neurodegenerative processes impacting cognition.
View Article and Find Full Text PDF

Utility of multi-biomarker panel on discriminating disease activity in patients with psoriatic arthritis.

Int Immunopharmacol

December 2024

Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China. Electronic address:

Article Synopsis
  • The study looked at how certain protein levels in the blood relate to how active the disease is in patients with Psoriatic Arthritis (PsA).
  • Researchers tested 48 different protein markers in 176 patients to see which ones could help indicate disease activity levels.
  • They found that six specific proteins were really good at predicting high disease activity, and their testing method performed better than a common test currently used.
View Article and Find Full Text PDF

Causes of Musculoskeletal Pain in Paget's Disease of Bone.

Calcif Tissue Int

November 2024

Centre for Genomics and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.

Article Synopsis
  • Paget's disease of bone (PDB) makes bones grow and change shape in a messy way, which can lead to problems like pain, deafness, and broken bones.
  • A study with 168 people found that about 73% of them had musculoskeletal pain, mainly because of osteoarthritis in joints away from the PDB affected areas.
  • The research showed that pain was more common in older folks and women, and highlighted the need to check each person's pain to treat it correctly.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!